Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine

Next Previous
X
Search
Trial Profile

A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 31 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zolmitriptan (Primary) ; Erenumab; Galcanezumab
  • Indications Migraine
  • Focus Adverse reactions; Registrational
  • Acronyms ADAM
  • Sponsors Zosano Pharma

    • Most Recent Events

    • 26 May 2021 Results published in the Zosano Pharma media release Media Release.
    • 26 May 2021 According to a Zosano Pharma media release, data published in The Journal of Headache and Pain.
    • 06 Aug 2020 According to a Zosano Pharma media release, post-hoc efficacy analyses from this ZOTRIP study compared with the open-label long term safety study were presented as a virtual oral presentation on the 2020 American Headache Society's Virtual Annual Scientific Meeting Platform.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top